Consensus Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:32 2025-12-16 EST			After hours 16:30:11
98.27 ^USD	-1.98%		98.50	+0.23%

04:06pm	Sector Update: Health Care Stocks Retreat Late Afternoon	MT
03:34pm	Sector Update: Health Care	MT

Evolution of the Average Target: Merck & Co., Inc.

Evolution of the Target Price: Merck & Co., Inc.

Changes in Analyst Recommendations: Merck & Co., Inc.

992efb1151176.THZUKCvDA_lzHKJemrmJ7z1n2mDWGg5TiQsvLzTfVbM.Kk4bb0WVdr44K5Vs9ovOtlhQkiXlanYk0V1qGA3vItU0GT9hYqpZlENO-w~92f8cb85f617cbbc832fef8890219d30

Analysts' recommendations: Merck & Co., Inc.

12-15	Merck Poised for Mid-Single-Digit Revenue Growth in Fiscal 2026, BofA Says	MT
12-12	Morgan Stanley Adjusts Merck & Co. PT to $102 From $100, Maintains Equalweight Rating	MT
12-10	HSBC Adjusts Price Target on Merck & Co. to $120 From $100, Maintains Buy Rating	MT
12-05	Guggenheim Adjusts Price Target on Merck & Co. to $122 From $104, Maintains Buy Rating	MT
12-04	Scotiabank Adjusts Price Target on Merck & Co to $120 From $105, Maintains Sector Outperform Rating	MT
12-01	Goldman Sachs Adjusts Price Target on Merck to $120 From $92, Maintains Buy Rating	MT
11-24	Wells Fargo Upgrades Merck & Co. to Overweight From Equalweight, Adjusts PT to $125 From $90	MT
11-19	Berenberg Adjusts Price Target on Merck & Co. to $95 From $90, Maintains Hold Rating	MT
11-19	Rothschild & Co Redburn Adjusts Price Target on Merck & Co. to $125 From $120, Maintains Buy Rating	MT
11-19	Berenberg Raises Price Target on Merck to $95 From $90, Keeps Hold Rating	MT
11-19	Jefferies Adjusts Price Target on Merck & Co. to $139 From $138, Maintains Buy Rating	MT
11-18	Deutsche Bank Lifts Price Target on Merck to $111 From $110, Keeps Hold Rating	MT
11-17	Sector Update: Health Care Stocks Softer Late Afternoon	MT
11-17	Jefferies Adjusts Price Target on Merck & Co. to $138 From $137, Maintains Buy Rating	MT
11-13	Scotiabank Initiates Merck & Co. at Sector Outperform With $105 Price Target	MT
11-10	Leerink Partners Adjusts Price Target on Merck to $114 From $107	MT
11-08	Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Phase 3 CORALreef Lipids Trial	CI
10-31	Morgan Stanley Adjusts Price Target on Merck & Co. to $100 From $98	MT
10-31	Goldman Sachs Adjusts Price Target on Merck & Co to $92 From $93	MT
10-30	(MRK) Merck Expects Full-Year Adjusted EPS Range $8.93 to $8.98, vs. FactSet Est of $8.91	MT
10-27	Merck & Co., Inc. Receives FDA Approval For Updated Indication Of WINREVAIR In Adults With PAH	CI
10-24	Merck announces FDA priority review for Keytruda
10-23	Merck Says FDA Granted Priority Review on Keytruda, Keytruda Qlex Applications for Bladder Cancer	MT
10-18	Merck says FDA accepts priority review for Keytruda based on Keynote-B96 data	RE
10-16	Merck & Co., Inc. Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients with Platinum-Resistant Recurrent Ovarian Cancer	CI

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MERCK & CO., INC.					+7.76%
	ELI LILLY AND COMPANY					+1.21%
	JOHNSON & JOHNSON					-3%
	ABBVIE INC.					+7.4%
	ROCHE HOLDING AG					+0.43%
	ASTRAZENECA PLC					+10.56%
	NOVARTIS AG					+0.39%
	NOVO NORDISK A/S					+24.3%
	AMGEN INC.					+0.18%
	GILEAD SCIENCES, INC.					+10.52%
	Average					+5.98%
	Weighted average by Cap.					+4.15%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

100.26USD

Average target price

108.04USD

Spread / Average Target

+7.76%

High Price Target

139.00USD

Spread / Highest target

+38.64%

Low Price Target

82.00USD

Spread / Lowest Target

-18.21%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Morgan Stanley
HSBC
Guggenheim
Scotiabank
Goldman Sachs
Wells Fargo Securities
Jefferies & Co.
Berenberg Bank
Rothschild & Co Redburn
Deutsche Bank Securities
Leerink Partners
DBS Bank
Daiwa Securities
JPMorgan Chase
Cantor Fitzgerald
Citigroup
BMO Capital
Redburn Atlantic
Bernstein
TD Cowen
UBS
Truist Securities
CFRA
Argus
Barclays
Wolfe Research
Zacks Investment Research
Societe Generale
BofA Securities
Atlantic Equities
Credit Suisse
SVB Securities LLC
Cowen
SVB Leerink
RBC Capital Markets
RBC	Randall Stanicky
JPMORGAN